StockMacro
Company, fund or insider

Help

Menu

Vyome

$1.20 -48% in 6 monthsMarket cap $8.4M

HIND on XNAS, Health Care, Vyome Holdings, Inc., job postings

Measures activity, not value. Not investment advice.

Stock fell 75% in a year and 35% in one month, with $7M cash against a $3.8M loss.

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Industry
Pharmaceutical preparations (Health Care)
Employees
18
Website
vyometx.com
Listed
Nasdaq, US
Last results
25 Aug 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $58K, net loss $885K.
Quarter to 31 Mar 2022: revenue $2.4M, net income -$8.2MQuarter to 31 Mar 2022: revenue $2.4M, net income -$8.2MQuarter to 30 Jun 2022: revenue $2.9M, net income -$9.6MQuarter to 30 Jun 2022: revenue $2.9M, net income -$9.6MQuarter to 30 Sep 2022: revenue $2.8M, net income -$11.8MQuarter to 30 Sep 2022: revenue $2.8M, net income -$11.8MQuarter to 31 Dec 2022: revenue $3.1M, net income -$16.5MQuarter to 31 Dec 2022: revenue $3.1M, net income -$16.5MQuarter to 31 Mar 2023: revenue $2.3M, net income -$2.7MQuarter to 31 Mar 2023: revenue $2.3M, net income -$2.7MQuarter to 30 Jun 2023: revenue $2.3M, net income -$3.5MQuarter to 30 Jun 2023: revenue $2.3M, net income -$3.5MQuarter to 30 Sep 2023: revenue $2.2M, net income -$3.5MQuarter to 30 Sep 2023: revenue $2.2M, net income -$3.5MQuarter to 31 Dec 2023: revenue $2.0M, net income -$1.7MQuarter to 31 Dec 2023: revenue $2.0M, net income -$1.7MQuarter to 31 Mar 2024: revenue $1.9M, net income -$2.2MQuarter to 31 Mar 2024: revenue $1.9M, net income -$2.2MQuarter to 30 Jun 2024: revenue $2.0M, net income -$1.6MQuarter to 30 Jun 2024: revenue $2.0M, net income -$1.6MQuarter to 30 Sep 2024: revenue $2.3M, net income -$1.6MQuarter to 30 Sep 2024: revenue $2.3M, net income -$1.6MQuarter to 31 Dec 2024: revenue $1.8M, net income -$1.8MQuarter to 31 Dec 2024: revenue $1.8M, net income -$1.8MQuarter to 31 Mar 2025: revenue –, net income $1.5MQuarter to 30 Jun 2025: revenue –, net income -$2.6MQuarter to 30 Sep 2025: revenue $35K, net income -$8.4MQuarter to 30 Sep 2025: revenue $35K, net income -$8.4MQuarter to 31 Mar 2026: revenue $32K, net income -$963KQuarter to 31 Mar 2026: revenue $32K, net income -$963KQuarter to 30 Jun 2026: revenue $27K, net income -$686KQuarter to 30 Jun 2026: revenue $27K, net income -$686KQuarter to 30 Sep 2026: revenue $58K, net income -$885KQuarter to 30 Sep 2026: revenue $58K, net income -$885K
31 Mar 2022RevenueNet incomeNet losstallest bar $16.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$58K-$885K
30 Jun 2026$27K-$686K
31 Mar 2026$32K-$963K
30 Sep 2025$35K-$8.4M
30 Jun 2025–-$2.6M
31 Mar 2025–$1.5M
31 Dec 2024$1.8M-$1.8M
30 Sep 2024$2.3M-$1.6M
30 Jun 2024$2.0M-$1.6M
31 Mar 2024$1.9M-$2.2M
31 Dec 2023$2.0M-$1.7M
30 Sep 2023$2.2M-$3.5M
30 Jun 2023$2.3M-$3.5M
31 Mar 2023$2.3M-$2.7M
31 Dec 2022$3.1M-$16.5M
30 Sep 2022$2.8M-$11.8M
30 Jun 2022$2.9M-$9.6M
31 Mar 2022$2.4M-$8.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$3.8M -$10.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -82.8% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $7.0M $5.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.93
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.3 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
VyomeHIND (this company) $8.4Mloss–––
Lexaria BioscienceLEXX $8.5Mloss–-69%–
BioVieBIVI $8.6Mloss–––
Moleculin BiotechMBRX $8.2Mloss–––
CalciMedicaCALC $8.7Mloss–––
Palatin TechnologiesPTN $8.2Mloss1.7-47%-385%

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

1.7%

120K shares held by 13F filers (30 Sep 2026) of 7.0M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.3%

18K shares sold short (30 Oct 2026) of 7.0M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.6

18K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

21K shares sold short in the report before, 18K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

29%

29% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 39%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $1.20 on 20 Nov 2026, -75% over 12 months (12-month range $1.20 to $5.73)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $58K in the latest quarter, +67% on a year earlier.
Capital spending per quarter. Capital spending $36K in the latest quarter, +200% on a year earlier.
Institutional holders (13F filers). 12 13F filers reported holding it in the latest 13F quarter, +140% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
28 Aug 20268-K and other filingsDirector or officer change
28 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Aug 20258-K and other filingsChanged its auditor
19 Aug 20258-K and other filingsDirector or officer change
19 Aug 20258-K and other filingsCompleted an acquisition or asset sale
19 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 May 20258-K and other filingsDelisting notice or listing transfer
15 May 20258-K and other filingsReport will be filed late
1 Apr 20258-K and other filingsReport will be filed late
20 Mar 20258-K and other filingsDirector or officer change
20 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
14 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
13 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
7 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
6 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
21 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
15 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
20 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
2 Dec 20248-K and other filingsDelisting notice or listing transfer
9 Jul 20248-K and other filingsDirector or officer change
9 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Apr 20248-K and other filingsDelisting notice or listing transfer
9 Apr 20248-K and other filingsChanged its auditor
18 Jan 20248-K and other filingsDelisting notice or listing transfer
13 Oct 20238-K and other filingsDelisting notice or listing transfer
27 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
12 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
25 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
13 Apr 20238-K and other filingsEarlier financial statements can no longer be relied on
3 Apr 20238-K and other filingsReport will be filed late
3 Feb 20238-K and other filingsRegistered new securities for sale (S-1)
1 Feb 20238-K and other filingsRegistered new securities for sale (S-1)
26 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
12 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
20 Dec 20228-K and other filingsDirector or officer change
20 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 20228-K and other filingsReport will be filed late
2 Aug 20228-K and other filingsDirector or officer change
2 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jul 20228-K and other filingsDelisting notice or listing transfer
21 Jul 20228-K and other filingsChanged its auditor
13 May 20228-K and other filingsReport will be filed late
14 Apr 20228-K and other filingsChanged its auditor
1 Apr 20228-K and other filingsReport will be filed late
Insider net buying (open market)
Month from 1 Dec 2021: -$32K published
Month from 1 Jan 2022: -$18K published
Month from 1 Feb 2022: -$15K published
Month from 1 Mar 2022: -$11K published
Month from 1 Apr 2022: -$18K published
Month from 1 May 2022: -$12K published
Month from 1 Jun 2022: $3K published
Month from 1 Jul 2022: -$9K published
Month from 1 Aug 2022: -$8K published
Month from 1 Sep 2022: -$2K published
Month from 1 Oct 2022: -$2K published
Month from 1 Nov 2022: -$2K published
Month from 1 Dec 2022: -$63K published
Month from 1 Mar 2023: -$4K published
Month from 1 Jul 2023: $26K published
Month from 1 Nov 2023: -$386 published
Month from 1 Aug 2024: -$38.8 published
Revenue per quarter
Quarter ended 31 Mar 2021: $3.2M; public on 24 May 2022
Quarter ended 31 Mar 2022: $2.4M, -24% on a year earlier; public on 24 May 2022
Quarter ended 30 Jun 2022: $2.9M, -18% on a year earlier; public on 20 Aug 2022
Quarter ended 30 Sep 2022: $2.8M, -25% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $3.1M; public on 18 Apr 2023
Quarter ended 31 Mar 2023: $2.3M, -6.3% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $2.3M, -22% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $2.2M, -23% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $2.0M, -36% on a year earlier; public on 2 Apr 2024
Quarter ended 31 Mar 2024: $1.9M, -15% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $2.0M, -13% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $2.3M, +6.4% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $1.8M, -8.9% on a year earlier; public on 5 Apr 2025
Quarter ended 30 Sep 2025: $35K, -98% on a year earlier; public on 15 Nov 2025
Quarter ended 31 Mar 2026: $32K; public on 13 May 2026
Quarter ended 30 Jun 2026: $27K; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $58K, +67% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $67K, +24% on a year earlier; public on 9 Apr 2022
Quarter ended 31 Mar 2022: $7K; public on 24 May 2022
Quarter ended 30 Jun 2022: $12K; public on 20 Aug 2022
Quarter ended 30 Sep 2022: $33K, -63% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $79K, +18% on a year earlier; public on 18 Apr 2023
Quarter ended 31 Mar 2023: $7K, 0% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $36K, +200% on a year earlier; public on 8 Aug 2023
Institutional holders (13F filers)
30 Sep 2025 report: 5; public on 14 Nov 2025
31 Dec 2025 report: 8; public on 17 Feb 2026
31 Mar 2026 report: 9; public on 15 May 2026
30 Jun 2026 report: 12; public on 14 Aug 2026
30 Sep 2026 report: 12; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short sale volume on FINRA-reported off-exchange venues (TRFs + ADF), shares per day at 7,325 (20 Nov 2026), 24× its normal reading; higher than 67% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $58K in the latest quarter, +67% on a year earlier.
  • Capital spending per quarter: Capital spending $36K in the latest quarter, +200% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 59 insider trades

No trades in the last 90 days; the latest was filed 13 Aug 2024. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Aug 2024Thomas StankovichChief Financial OfficerSell172$0.23$38.8Form 4
8 Nov 2023Thomas StankovichChief Financial OfficerSell435$0.89$386Form 4
19 Jul 2023Thomas StankovichChief Financial OfficerSell106$1.47$156Form 4
6 Jul 2023Thomas StankovichChief Financial OfficerSell303$2.46$746Form 4
6 Jul 2023Thomas StankovichChief Financial OfficerBuy17,702$1.52$27KForm 4
7 Mar 2023Thomas StankovichChief Financial OfficerSell418$8.87$4KForm 4
20 Dec 2022Thomas StankovichChief Financial OfficerSell372,113$0.17$63KForm 4
10 Nov 2022Thomas StankovichChief Financial OfficerSell8,393$0.27$2KForm 4

12 institutions reported shares at the end of Q3 2026, 2% of the shares outstanding; 1 opened a position, 1 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Susquehanna International Group, LLP27K0.38%$51K+16K+164%
Geode Capital Management, LLC26K0.36%$49K-213-0.8%
Vanguard Capital Management LLC15K0.21%$29K+5,464+58%
Focus Partners Wealth15K0.21%$28KNo change
HRT Financial LP14K0.20%-6,484-32%
Vanguard Fiduciary Trust Co12K0.17%$24KNo change
Royal Bank of Canada5,8560.08%$11KNo change
UBS Group AG3,0910.04%$6K-8,817-74%
Tower Research Capital LLC (TRC)2,5160.04%$5K+708+39%
FMR LLC (Fidelity)1,0000.01%$2KNew+1,000

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Aug 2026Director or officer change8-K
25 Feb 2026Signed a major agreement8-K
23 Dec 2025Signed a major agreement8-K
20 Aug 2025Signed a major agreement; Changed its auditor8-K
19 Aug 2025Director or officer change; Completed an acquisition or asset saleSame filing: sold shares privately, changed shareholder rights, changed its bylaws or fiscal year8-K
3 Jul 2025Signed a major agreement8-K
12 Jun 2025Signed a major agreement8-K
30 May 2025Delisting notice or listing transfer8-K

The 5 newest of 16 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 28 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 28 Aug 2026Filings record

    Director or officer change

  3. 20 Aug 2025Filings record

    Changed its auditor

  4. 19 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 19 Aug 2025Filings record

    Director or officer change

  6. 19 Aug 2025Filings record

    Completed an acquisition or asset sale

  7. 30 May 2025Filings record

    Delisting notice or listing transfer

  8. 15 May 2025Filings record

    Report will be filed late

  9. 1 Apr 2025Filings record

    Report will be filed late

  10. 20 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 20 Mar 2025Filings record

    Director or officer change

  12. 14 Feb 2025Filings record

    Registered new securities for sale (S-1)

  13. 14 Feb 2025Filings record

    Registered new securities for sale (S-1)

  14. 13 Feb 2025Filings record

    Registered new securities for sale (S-1)

  15. 7 Feb 2025Filings record

    Registered new securities for sale (S-1)

  16. 6 Feb 2025Filings record

    Registered new securities for sale (S-1)

  17. 21 Jan 2025Filings record

    Registered new securities for sale (S-1)

  18. 15 Jan 2025Filings record

    Registered new securities for sale (S-1)

  19. 20 Dec 2024Filings record

    Registered new securities for sale (S-1)

  20. 2 Dec 2024Filings record

    Delisting notice or listing transfer

  21. 9 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 9 Jul 2024Filings record

    Director or officer change

  23. 10 Apr 2024Filings record

    Delisting notice or listing transfer

  24. 9 Apr 2024Filings record

    Changed its auditor

  25. 18 Jan 2024Filings record

    Delisting notice or listing transfer

  26. 13 Oct 2023Filings record

    Delisting notice or listing transfer

  27. 27 Sep 2023Filings record

    Registered new securities for sale (S-1)

  28. 12 Sep 2023Filings record

    Registered new securities for sale (S-1) (dated 11 Sep 2023)

  29. 25 Aug 2023Filings record

    Registered new securities for sale (S-1)

  30. 7 Jul 2023Insiders record

    STANKOVICH THOMAS (Chief Financial Officer) bought 17,702 shares of RSLS ($26,907) (dated 6 Jul 2023)

  31. 13 Apr 2023Filings record

    Earlier financial statements can no longer be relied on

  32. 3 Apr 2023Filings record

    Report will be filed late

  33. 3 Feb 2023Filings record

    Registered new securities for sale (S-1)

  34. 1 Feb 2023Filings record

    Registered new securities for sale (S-1)

  35. 26 Jan 2023Filings record

    Registered new securities for sale (S-1)

  36. 12 Jan 2023Filings record

    Registered new securities for sale (S-1)

  37. 20 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 20 Dec 2022Filings record

    Director or officer change

  39. 15 Aug 2022Filings record

    Report will be filed late

  40. 2 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 109 entries; narrow the window or the kind of data to see older ones.

Not listed: 184 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001427570
Ticker
HIND
Domain
vyometx.com
Hq location
CA|SAN CLEMENTE|92673 (1 unverified)
Name
ea028082101ex21-1.htm, EX-21.1, LiveChain, Inc., OBALON THERAPEUTICS INC and 6 more
  • SEC Form 13F institutional holdings45 data points30 Sep 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)223 records8 Sep 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)794 data points31 Dec 2013 to 9 Nov 2026
  • SEC Form 4 insider transactions59 records, 132 data points12 Oct 2016 to 13 Aug 2024
  • FINRA short interest (twice monthly)90 data points15 Aug 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)640 data points15 Aug 2025 to 20 Nov 2026